Anna Broder1, Wenzhu B Mowrey2, Hina N Khan3, Bojana Jovanovic4, Alejandra Londono-Jimenez3, Peter Izmirly5, Chaim Putterman4. 1. Division of Rheumatology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY. Electronic address: abroder@montefiore.org. 2. Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY. 3. Department of Medicine, Montefiore Medical Center, Bronx, NY. 4. Division of Rheumatology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY. 5. Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY.
Abstract
OBJECTIVES: The presence of tubulointerstitial damage (TID) on renal biopsy is considered to be a late sequela of lupus nephritis (LN). The objective of this study was to determine if TID predicts progression to end stage renal disease (ESRD) in LN patients without advanced kidney disease. METHODS: All SLE patients with an index biopsy consistent with LN between January 2005 and July 2015, and eGFR ≥ 30mL/min/1.73m2 were included. Moderate-to-severe TID was defined as the presence of moderate-to-severe tubular atrophy and/or interstitial fibrosis. Time to ESRD was defined as time from the index biopsy date to incident ESRD date; non-ESRD patients were censored at the time of death or the last visit before December 2015. Time-dependent analyses were conducted to evaluate whether moderate-to-severe TID was predictive of ESRD progression. RESULTS: Of the 131 LN patients with eGFR ≥ 30mL/min/1.73m2, 17 (13%) patients progressed to ESRD. Moderate-to-severe TID was present in 13% of biopsies with eGFR ≥ 60mL/min/1.73m2 and in 33% of biopsies with eGFR between 30 and 60mL/min/1.73m2. Moderate-to-severe TID was associated with a higher risk of ESRD progression: adjusted hazard ratio (HR) = 4.1, 95% CI: 1.4-12.1, p = 0.01 for eGFR ≥ 30mL/min/1.73m2; HR = 6.2, 95% CI: 1.7-23.2, p = 0.008 for eGFR ≥ 60mL/min/1.73m2. There was no association between tubulointerstitial inflammation (TII) and ESRD progression. CONCLUSIONS: Moderate-to-severe TID, but not TII, was a strong predictor of ESRD progression independent of eGFR or glomerular findings, therefore, providing an important window for potential early interventions.
OBJECTIVES: The presence of tubulointerstitial damage (TID) on renal biopsy is considered to be a late sequela of lupus nephritis (LN). The objective of this study was to determine if TID predicts progression to end stage renal disease (ESRD) in LN patients without advanced kidney disease. METHODS: All SLEpatients with an index biopsy consistent with LN between January 2005 and July 2015, and eGFR ≥ 30mL/min/1.73m2 were included. Moderate-to-severe TID was defined as the presence of moderate-to-severe tubular atrophy and/or interstitial fibrosis. Time to ESRD was defined as time from the index biopsy date to incident ESRD date; non-ESRDpatients were censored at the time of death or the last visit before December 2015. Time-dependent analyses were conducted to evaluate whether moderate-to-severe TID was predictive of ESRD progression. RESULTS: Of the 131 LN patients with eGFR ≥ 30mL/min/1.73m2, 17 (13%) patients progressed to ESRD. Moderate-to-severe TID was present in 13% of biopsies with eGFR ≥ 60mL/min/1.73m2 and in 33% of biopsies with eGFR between 30 and 60mL/min/1.73m2. Moderate-to-severe TID was associated with a higher risk of ESRD progression: adjusted hazard ratio (HR) = 4.1, 95% CI: 1.4-12.1, p = 0.01 for eGFR ≥ 30mL/min/1.73m2; HR = 6.2, 95% CI: 1.7-23.2, p = 0.008 for eGFR ≥ 60mL/min/1.73m2. There was no association between tubulointerstitial inflammation (TII) and ESRD progression. CONCLUSIONS: Moderate-to-severe TID, but not TII, was a strong predictor of ESRD progression independent of eGFR or glomerular findings, therefore, providing an important window for potential early interventions.
Authors: C Morath; H Reuter; V Simon; E Krautkramer; W Muranyi; V Schwenger; P Goulimari; R Grosse; M Hahn; P Lichter; M Zeier Journal: Am J Transplant Date: 2008-09 Impact factor: 8.086
Authors: N Hiramatsu; T Kuroiwa; H Ikeuchi; A Maeshima; Y Kaneko; K Hiromura; K Ueki; Y Nojima Journal: Rheumatology (Oxford) Date: 2008-04-04 Impact factor: 7.580
Authors: Vladimir M Liarski; Natalya Kaverina; Anthony Chang; Daniel Brandt; Denisse Yanez; Lauren Talasnik; Gianluca Carlesso; Ronald Herbst; Tammy O Utset; Christine Labno; Yahui Peng; Yulei Jiang; Maryellen L Giger; Marcus R Clark Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: Cianna Leatherwood; Cameron B Speyer; Candace H Feldman; Kristin D'Silva; José A Gómez-Puerta; Paul J Hoover; Sushrut S Waikar; Gearoid M McMahon; Helmut G Rennke; Karen H Costenbader Journal: Semin Arthritis Rheum Date: 2019-06-11 Impact factor: 5.532
Authors: Brian R Stotter; Ellen Cody; Hongjie Gu; Ankana Daga; Larry A Greenbaum; Minh Dien Duong; Alexandra Mazo; Beatrice Goilav; Alexis Boneparth; Mahmoud Kallash; Ahmed Zeid; Wacharee Seeherunvong; Rebecca R Scobell; Issa Alhamoud; Caitlin E Carter; Siddharth Shah; Caroline E Straatmann; Bradley P Dixon; Jennifer C Cooper; Raoul D Nelson; Deborah M Levy; Hermine I Brunner; Priya S Verghese; Scott E Wenderfer Journal: Pediatr Nephrol Date: 2022-10-17 Impact factor: 3.651
Authors: Paul Hoover; Evan Der; Celine C Berthier; Arnon Arazi; James A Lederer; Judith A James; Jill Buyon; Michelle Petri; H Michael Belmont; Peter Izmirly; David Wofsy; Nir Hacohen; Betty Diamond; Chaim Putterman; Anne Davidson Journal: Arthritis Care Res (Hoboken) Date: 2020-01-13 Impact factor: 4.794
Authors: Amrie C Grammer; Peter E Lipsky; Kathryn M Kingsmore; Prathyusha Bachali; Michelle D Catalina; Andrea R Daamen; Sarah E Heuer; Robert D Robl Journal: Sci Rep Date: 2021-07-20 Impact factor: 4.379